alert icon Construction + COVID Info

Coming to a Cleveland Clinic location?
Cole Eye entrance closing
Visitation, mask requirements and COVID-19 information

Department Cleveland Clinic Lou Ruvo Center for Brain Health
Primary Location Lou Ruvo Center for Brain Health - Las Vegas
Type of Doctor Adults Only
Languages English
Surgeon No
Locations Specialties & Treatments

Treatment & Services

  • Neurology
View all 1 Treatment & Services +

Specialty in Diseases & Conditions

  • Acute Disseminated Encephalomyelitis (ADEM)
  • Devic's Disease (Neuromyelitis Optica)
  • Multiple Sclerosis
  • Optic Neuritis
  • Transverse Myelitis
View all 5 Specialties +


Is Cleveland Clinic Nevada Part of Your Insurance?

For questions about accepted insurance plans for our Nevada locations and specific plan products including Medicare, please contact your insurance carrier directly.

View All Plans

About Carrie Hersh, DO

Carrie M. Hersh, DO, MSc, FAAN joined the faculty at Cleveland Clinic Lou Ruvo Center for Brain Health in August 2015 where she also serves as Associate Professor of Neurology at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and directs the Multiple Sclerosis (MS) Health and Wellness Program at the Lou Ruvo Center for Brain Health. She completed a neuroimmunology fellowship at the Cleveland Clinic Mellen Center for MS Treatment and Research through a National MS Society Sylvia Lawry Award. She also earned a master’s degree in clinical research through the Clinical Research Scholars Program (CRSP) at Case Western Reserve University. She completed her adult neurology residency training at Cleveland Clinic and graduated medical school with honors from Nova Southeastern University-College of Osteopathic Medicine. She earned her BS degree in microbiology and neurobiology at University of Florida, graduating summa cum laude, and is a member of Phi Beta Kappa.

A patient advocate and proponent of shared decision making, Dr. Hersh specializes in multiple sclerosis and related neuroimmunological disorders. She is particularly interested in real-world evidence, outcomes-based research and comparative effectiveness studies. She serves as PI of multiple investigator-initiated studies and clinical trials evaluating the effects of disease modifying therapies and wellness interventions on clinical, radiographic, and patient-reported outcomes. She is the lead investigator of the Multiple Sclerosis Partners Advancing Technology and Health Solutions program at Cleveland Clinic Lou Ruvo Center for Brain Health and serves on the study steering committee for the PCORI-funded DELIVER-MS clinical trial. Dr. Hersh is a frequent lecturer on multiple sclerosis and related disorders topics at national and international meetings and has authored more than 100 publications, including peer-reviewed scientific journal articles, invited reviews, editorials, abstracts, and book chapters. Currently, she is Chair of the Healthcare Advisory Council for the Multiple Sclerosis Association of America, Chair of the National MS Society’s regional Healthcare Provider Council, serves on the Board of Governors of the Consortium of MS Centers as Co-Chair of the Scientific Program Committee, and serves on numerous national and international steering committees, expert panels, and advisory boards. 

Education & Professional Highlights

Education & Professional Highlights


Education & Fellowships

Graduate School - Case Western Reserve University School of Medicine
Clinical Research
Cleveland, OH USA

Fellowship - Cleveland Clinic
Cleveland, OH USA

Residency - Cleveland Clinic
Cleveland, OH USA

Internship - Cleveland Clinic
Internal Medicine
Cleveland, OH USA

Medical Education - Nova Southeastern University
Davie, FL USA

Undergraduate - University of Florida
Gainesville, FL USA

Professional Highlights

  • Peer Reviewed Publications:

    Hersh, CM. The effects of environmental challenges on nociception/orphanin FQ-induced anxiety. J Undergrad Res. 2005; 6(7).
  • Hersh, C, Rae-Grant, A. Extended-release dalfampridine in the management of MS-related walking impairment. Ther Adv Neurol Disord. 2012; 5(4):199-204. doi: 10.1177/1756285612447091. PMID: 22783369.
  • Hersh, CM, Cohen, JA. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Immunotherapy. 2014; 6(3): 249-259. doi: 10.2217/imt.14.7. PMID: 24762071.
  • Hersh, CM, Hara-Cleaver, C, Rudick, RA, Cohen, JA, Bermel, RA, Ontaneda, D. Experience with fingolimod in clinical practice. Int J Neurosci. 2015; 125(9):678-85. doi: 10.3109/00207454.2014.969839. PMID: 25271798.
  • Hersh, CM, Love, TE, Cohn, S, Hara-Cleaver, C, Bermel, RA, Fox, RJ, Cohen, JA, Ontaneda, D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Mult Scler Relat Disord. 2016 Nov; 10:44-52. doi: 10.1016/j.msard.2016.08.002. PMID: 27919497.
  • Hersh, CM, John, S, Subei, A, Willis, MA, Kosmorsky, G, Prayson, RA, Bhimraj, A. Optic neuropathy and stroke secondary to invasive Aspergillus in an immunocompetent patient. J Neuroophthalmol. 2016 Dec; 36(4):404-407. doi: 10.1097/WNO.0000000000000361. PMID: 27031126.
  • Hersh, CM, Love, TE, Bandyopadhyay, A, Cohn, S, Hara-Cleaver, C, Bermel, RA, Fox, RJ, Cohen, JA, Ontaneda, D. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Mult Scler J Exp Transl Clin. 2017 Aug; 3(3):2055217317715485. doi: 10.1177/2055217317715485. PMID: 28890796.
  • Moss, B, Rensel, MR, Hersh, CM. Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics. 2017 Oct; 14(4):999-1017. doi: 10.1007/s13311-017-0563-6. PMID: 28785958.
  • Vollmer, B, Ontaneda D, Bandyopadhyay, A, Cohn, S, Nair, K, Sillau, S, Bermel, R, Corboy, J, Fox, RJ, Vollmer, T, Cohen, JA, Alvarez, A, Hersh, CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in two centers. Neurol Clin Pract. 2018 Aug; 8(4):292-301. doi: 10.1212/CPJ.0000000000000487. PMID: 30140580.
  • Hua, LH, Hersh, CM, Morten, P, Kusel, J, Lin, F, Cave, J, Varga, S, Herrera, V, Ko, J. The impact of price reductions after loss of exclusivity in a cost-effective analysis: fingolimod versus intramuscularly-administered interferon beta-1a for the treatment of relapsing forms of multiple sclerosis. J Manag Care Spec Pharm. 2019 Apr; 25(4):490-498. doi: 10.18553/jmcp.2019.25.4.490. PMID: 30917079.
  • Vollmer, B, Ontaneda, D, Harris, H, Nair, K, Bermel, R, Corboy, J, Fox, RJ, Vollmer, T, Cohen, JA, Alvarez, A, Hersh, CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15; 407:116498. doi:10.1016/j.jns.2019.116498. PMID: 31644992.
  • Conway, DS, Hersh, CM, Harris, HC, Hua, LH. Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population. Mult Scler J Exp Transl Clin. 2020 Jan 27; 6(1): 2055217320902488. doi: 10.1177/2055217320902488. PMID: 32064117.
  • Hua, LH, Harris, H, Conway, D, Hersh, CM. Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy. J Neurol. 2020 Aug;267(8):2214-2220. doi: 10.1007/s00415-020-09816-1. PMID: 32270292.
  • Ontaneda, D, Tallantyre, EC, Raza, PC, Planchon, S, Nakamura, K, Miller, D, Hersh, C, Craner, M, Bale, C, Chaudhry, B, Gunzler, DD, Love, TE, Gerry, S, Coles, A, Cohen, JA, Evangelou, N. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemp Clin Trials. 2020 Aug;95:106009. doi: 10.1016/j.cct.2020.106009. PMID: 32320842.
  • Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups and Clinical Investigators: Hersh, C (I did not work closely with any of the listed authors on this publication). Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246.N Engl J Med. 2020. PMID: 32757523.
  • Mowry, E, Bermel, RA, Williams, JR, Benzinger, T, de Moor, C, Fisher, E, Hersh, CM, Hyland, MH, Izbudak, I, Jones, SE, Kieseier, BC, Kitzler HH, Krupp, L, Lui, YW, Montalban, X, Naismith, RT, Nicholas,, JA, Pellegrini, F, Rovira, A, Schulze, M, Tackenberg, B, Tintore, M, Tivarus, ME, Ziemssen, T, Rudick, RA. Harnessing real-world data to inform decision-making: multiple sclerosis partners advancing technology and health solutions (MS PATHS). Front Neurol. 2020 Aug 7;11:632. doi: 10.3389/fneur.2020.00632. PMID: 32849170.
  • Hersh, CM, Harris, H, Ayers, M, Conway, D. Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod. Mult Scler J Exp Transl Clin. 2020 Oct 13;6(4):2055217320959815. doi: 10.1177/2055217320959815. PMID: 33110616.
  • Hua, LH, Hersh, CM, Tian, F, Mowry, EM, Fitzgerald, KC. Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60. Mult Scler Relat Disord. 2020 Nov 23;47:102637. doi: 10.1016/j.msard.2020.102637. PMID: 33276238.
  • Hersh, CM, Harris, H, Conway, D, Hua, LH. Impact of switching from natalizumab to moderate versus high efficacy DMT in clinical practice. Neurol Clin Pract. 2020 Dec 10 (6) e53-e65; doi: 10.1212/CPJ.0000000000000809. PMID: 33510948. Received “Notable This Week” and “Most Read Article” designations.
  • Morrison-Banks, E, Michtich, K, Hersh, CM. How the COVID-19 pandemic has changed multiple sclerosis clinical practice: results of a nationwide provider survey. Mult Scler Relat Disord. 2021 Mar 18;51:102913. doi: 10.1016/j.msard.2021.102913. PMID: 33839482.
  • Hersh, CM, Brook, RA, Beren, IA, Rohrbacker, NJ, Lebson, L, Henke, C, Phillips, A. The implications of suboptimal treatment outcomes with disease-modifying drugs in employees with multiple sclerosis. J Med Econ. 2021 Mar 19;24:1:479-486.doi: 10.1080/13696998.2021.1906013. PMID: 33739915.
  • Hersh, CM, Kieseier, B, deMoor, C, Miller, D, Campagnolo, D, Williams, JR, Fitzgerald, K, Xiong, K, McGinley, M, Hyland, M, Ruddick, R, Ziemssen, T, Koulinska, I. Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: results of MS PATHS. 2021 Apr 15;7(2). doi: 10.1177/20552173211004634.
  • Ziemssen, T, Giovannoni, G, Alvarez, E, Bhan, V, Hersh, C, Hoffman, O, Oreja-Guevara, C, Robles-Cedeno, R, Trojano, M, Vermersch, P, Dobay, P, Khwaja, M, Stadler, B, Rauser, B, Hach, T, Piani-Meier, D, Burton, J. MSProDiscussTM, a useful digital tool to evaluate early signs of multiple sclerosis disease progression in a real world setting. J Med Internet Res. J Med Internet Res. 2021 Oct 6;23(10):e29558. doi: 10.2196/29558. PMID: 34612826.
  • Cohen, JA, Bermel, RA, Grossman, CI, Hersh, CM, Hyland, H, Mowry, EM, Naismith, R, Naylor, ML, Nicholas, J, Rajbhandari, R, Singh, CM, Tintorè, M, Zabalza, A, Ziemssen, T, Williams, JR, Montalban, X, on behalf of the MS PATHS Investigators. IgG Immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within MS PATHS. Mult Scler. 2022 Jan 7;13524585211061343. doi: 10.1177/13524585211061343. PMID: 34994577.
  • Hersh, CM, Altincatal, A, Kapadia, S, de Moor, C, Rudick, R, Williams, JR, Miller, C, Koulinska, I. Real-world effectiveness of dimethyl fumarate versus fingolimod in a cohort of patients with multiple sclerosis using standardized, quantitative outcome metrics. Mult Scler J Exp Transl Clin. 2022 Jan 7;8(1):20552173211069852. doi: 10.1177/20552173211069852. PMID: 35024161.
  • Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial: Hersh, CM. Lancet Neurol. 2022 Apr 25:S1474-4422(22)00143-0. doi: 10.1016/S1474-4422(22)00143-0. Epub ahead of print. PMID: 35483387.
  • Conway DS, Briggs FB, Mowry EM, Fitzgerald KC, Hersh, CM. Racial disparities in hypertension management among multiple sclerosis patients. Mult Scler Relat Disord. 2022 Jun 15;64:103972. doi: 10.1016/j.msard.2022.103972. Epub ahead of print. PMID: 35728435.


  • Psychiatry and Neurology - Neurology

Awards & Honors

  • 2001 University of Florida Honors Program
  • 2002 Phi Eta Sigma Honor Society, UF
  • 2002 National Society of Collegiate Scholars
  • 2002 Golden Key International Honor Society, UF
  • 2004 National Dean’s List
  • 2004 National Society of Collegiate Scholars Merit Award, UF
  • 2004 Presidential Recognition, UF
  • 2004 Chancellor’s List, UF
  • 2004 University Scholars Program, UF
  • 2004 Phi Kappa Phi Honor Society, UF
  • 2004 Phi Beta Kappa, UF
  • 2005-2009 Dean’s List, NSU
  • 2006 Sigma Sigma Phi Honor Society, NSU
  • 2009 Psi Sigma Alpha National Osteopathic Honor Society, NSU
  • 2012 7th Annual MASTER MS Fellowship Program
  • 2014 Consortium of MS Centers (CMSC) Scholarship Award
  • 2015 American Academy of Neurology (AAN) Fellows Scholarship Award
  • 2015 Neurological Institute Research Day Clinical Fellow Award, CCF
  • 2016 Travel Grant Award, European Committee for Treatment and Research in MS (ECTRIMS) 2016
  • 2016 Top Score Poster, ECTRIMS 2016
  • 2016 Top Score Poster, ECTRIMS 2016
  • 2016 Editor’s Choice for original research, Multiple Sclerosis and Related Disorders journal article “Comparative efficacy and discontinuation of dimethyl fumarate andfingolimod in clinical practice at 12-month follow-up”
  • 2017 Travel Grant Award, ECTRIMS 2017
  • 2018 Healthcare Headliner Award in Research/Science, Vegas Inc.
  • 2018 Top Score Poster, ECTRIMS 2018
  • 2019 Top Score Poster, ECTRIMS 2019
  • 2020 Fellow of the American Academy of Neurology (FAAN)


  • Consortium of Multiple Sclerosis Centers
  • National Multiple Sclerosis Society
  • American Academy of Neurology
Research & Publications

Research & Publications

See publications for Carrie Hersh, DO.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 1/31/2022, Dr. Hersh has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Hersh receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Multiple Sclerosis Association of America

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Patient Satisfaction Reviews

111 Patient Satisfaction Reviews

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

The comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Cleveland Clinic.

Overall Star Ratings
4.9 out of 5
Explains 4.9
Courtesy, Respect & Concern 4.9
Patient Rating of Doctor 4.9

32 Patient Comments

Reviewed on Dec 7, 2022

Dr Carrie Hersch, was awesome

Reviewed on Dec 2, 2022

Dr Hersh is great.

Reviewed on Nov 30, 2022

Dr. Hersh eases my mind yet explains everything good or bad. Couldn't ask for a better provider.

Reviewed on Nov 4, 2022

She is the best and very knowledgeable.

Reviewed on Oct 18, 2022

A step above the ordinary. The teller of truths. That's what Dr Carrie Hirsch at the Cleveland clinic in Las Vegas Nevada means to me

Reviewed on Oct 18, 2022

There are none finer than Dr Carrie Hersh as far as I'm concerned. She tells the truth. That's really all we want to know is the truth.

Reviewed on Oct 7, 2022

Dr. Hersh is the most human and wonderful neurologist I have had in the 40 years of having my illness. She cares about all aspects of my life because they may affect my illness. She is astute, conscientious, and thorough. I wish everyone could have her for their doctor, and I am certainly grateful she is mine.

Reviewed on Oct 5, 2022

Dr. Hersh and her staff are very helpful and knowledgeable.

Reviewed on Oct 5, 2022

Dr. Hersh is amazing and took a lot of time with me to discuss going off my medication.

Reviewed on Oct 5, 2022

Dr Hersh is my favorite because she actually cares, listens, and even took a good majority of the time listening and explaining medicine to me. Can't really ask for a better provider.

Reviewed on Sep 23, 2022

Dr Hersch is amazing. She is kind and compassionate. She is very thorough with her explanations and show genuine interest in her patients

Reviewed on Sep 21, 2022

Could not be happier with Dr. Hersh

Reviewed on Sep 9, 2022

Dr.Hersh is so caring n professional always so pleasant and understanding It was so wonderful to meet her n explained thoroughly my situation Thanks again

Reviewed on Jul 29, 2022

Dr. Hersh is the best!

Reviewed on Jul 19, 2022

Dr. Hersh was great!! No complaints only accolades for her knowledge, demeanor, and empathy. At this point, I could not have asked for a better doctor to partner with for this journey I must travel.

Reviewed on Jul 15, 2022

Dr Hersh is amazing, caring, just the best!

Reviewed on Jul 12, 2022

I am so thankful and blessed to be under the care of Dr Hersh. She is wonderful in every way. Her knowledge Is surpassed only by the care she has shown to me.

Reviewed on May 25, 2022

I want to discontinue DMT. Dr went to source MRI. I may not like outcome but really like thoroughness.

Reviewed on May 17, 2022

This are very troubling times over all and Dr. Hersh was so kind and helpful. She took her time and made it just about me. Thank you!

Reviewed on May 10, 2022

It took me over 6 weeks before I could schedule an appointment. It was 4 months from the day of my referral before I saw Dr. Hersh.

Reviewed on Apr 22, 2022

Hi travel from New Mexico every 6 months because of the quality of care and the bedside manner of my doctor. I would follow her to the ends of the Earth in order to continue to see her and receive care I'm just thankful at the Cleveland clinic maintained such a high standard of physicians nurses and support staff.

Reviewed on Apr 20, 2022

Dr. Herschel is always very good at listening to my questions and providing me answers.

Reviewed on Apr 19, 2022

Dr. Hersh actively listened to history, reviewed my medical records with me from my MS specialist at Northwestern. Dr. Hersh exhibited patience and performed a thorough neurological exam.

Reviewed on Apr 19, 2022

I would without any reservations recommend Dr. Hersh.

Reviewed on Apr 15, 2022

Dr. Hersh is the best I have had in 40 years of having MS. She makes me feel safe and well cared for. She is knowledgeable and comforting.

Reviewed on Apr 15, 2022

Dr. Carrie Hersh is a Wonderful Neurologist! She is Friendly, Kind and Professional! Dedicated to her patients!

Reviewed on Feb 25, 2022

Excellent doctor!

Reviewed on Feb 11, 2022

She's the best.

Reviewed on Feb 4, 2022

Dr. Hersh is THE best!

Reviewed on Jan 28, 2022

I consider myself fortunate to have her as my Doctor.

Reviewed on Jan 28, 2022

I love my visits w Dr Hersh. She's a linear thinker so my visits are all-encompassing and very thorough.

Reviewed on Jan 28, 2022

Everything related to my visits to Dr. Hersh & the Cleveland Clinic is the best care I've ever experienced.

Back to Top